Catalent, Inc., a global provider of delivery technologies and development services for pharma/biopharma and consumer health products, has agreed to acquire Accucaps Industries Ltd., a Canadian-based developer and manufacturer of OTC, high potency and conventional pharmaceutical softgels. Financial details were not disclosed.
 
The acquisition expands Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of pharmaceutical products supplied to North America, and two facilities offering softgel development, manufacturing and packaging.
 
Accucaps’ 500 employees at its facilities in Windsor and Strathroy, ON, will join Catalent’s network of 11 Softgel Technologies facilities. The Accucaps facilities house blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise.

Dr. Aris Gennadios, Catalent’s president of Softgel Technologies, said, “Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments.”